Portfolio Manager Factsheet
Merck & Co presented game changing data for their imunno-oncology drug, Keytruda (pembrolizumab), at an American Association of Cancer Research meeting. Regeneron Pharmaceuticals’ flagship product is a physician administered drug, Eyelea (aflibercept), for the treatment of certain types of blindness. Investor concerns continued to grow that the Trump administration’s changes to drug policy many unduly impact Eyelea’s price.
Worldwide Healthcare Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers (IFAs) to retail private investors. The shares are excluded from the Financial Conduct Authority's (FCA's) restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.